BridgeMD
New treatment option for Colorectal Cancer
Official title Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases
ClinicalTrials.gov ID: NCT06200831
What this study is testing
- What it's testing
- The SYLMET Trial is a randomized trial to compare simultaneous and two-staged resection of primary colorectal and synchronous liver metastases. This is an investigator-initiated, multicentre, randomized controlled trial to assess complications (primary endpoint), survival, cost-effectiveness, and quality of life (secondary endpoints).This trial will include patients with resectable primary tumour in the colon or upper rectum with less than five liver metastases that is possible to treat with surgical resection and/or ablation (RFA/MWA) at time of evaluation.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Age 18-80 years old.
- Both CRC and liver metastases in situ at time of evaluation.
- Resectable primary tumor in the colon or upper rectum.
- Less than 5 liver metastases, evaluated by the multidisciplinary tumor board meeting as possible to treat with surgical resection and/or ablation...
You likely can't join if
- Unresectable primary tumor.
- Locally advanced primary tumor (T4).
- Primary tumor in the lower rectum with indication for abdominoperineal resection.
- Acute or imminent bowel obstruction.
- Perforation or major bleeding from the primary tumor.
- Pre-treatment of the primary tumor with a colon stent.
See the full eligibility criteria
- Age 18-80 years old.
- Both CRC and liver metastases in situ at time of evaluation.
- Resectable primary tumor in the colon or upper rectum.
- Less than 5 liver metastases, evaluated by the multidisciplinary tumor board meeting as possible to treat with surgical resection and/or ablation (RFA/MWA).
- Unresectable primary tumor.
- Locally advanced primary tumor (T4).
- Primary tumor in the lower rectum with indication for abdominoperineal resection.
- Acute or imminent bowel obstruction.
- Perforation or major bleeding from the primary tumor.
- Pre-treatment of the primary tumor with a colon stent.
- Liver resection requiring resection of more than 2 adjacent segments (Couinaud).
- Liver metastases planned treated with irreversible electroporation (IRE).
- Non-resectable lung metastases.
- Metastases outside of liver (besides resectable lung metastases).
- Eastern Cooperative Oncology Group (ECOG) Performance status ≥ 3.
The study team makes the final eligibility decision.
Where it's taking place
- Oslo, Norway
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Oslo, Norway. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.